3:58 PM
 | 
Dec 06, 2017
 |  BC Extra  |  Politics & Policy

FDA issues guidance for rare pediatric disease drug development

FDA issued draft guidance on Wednesday aimed at accelerating clinical development of treatments for pediatric rare diseases. The guidance builds upon a joint proposal between FDA and EMA that encourages companies to join multidrug platform trials (see BioCentury, July 28).

FDA proposed the use...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >